Neoadjuvant Carboplatin, Weekly Abraxane and Trastuzumab in HER2+ Breast Cancer

NCT00617942 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Cohort 1 neo-adjuvant
DRUG: Cohort 2 neo-adjuvant
DRUG: Cohort 1 adjuvant
DRUG: Cohort 2 adjuvant

Sponsor

William Sikov MD

Collaborators

[object Object]